Oncology Compass

Elizabeth H. Blackburn, PhD, was awarded the Nobel Prize in Physiology or Medicine in 2009, alongside Carol W. Greider and Jack W. Szostak for their discoveries related to the structure and function of telomeres and the enzyme telomerase. In addition to the Nobel Prize, she has received nearly every major award in science, including the Lasker, Gruber, and Gairdner prizes. In 2007, she was named to the TIME 100, the magazine's annual list of the most influential people in the world. This remarkable molecular biologist and biochemist celebrates her 76th birthday today.

The first known description of pancreatic cancer dates back to 1761 when Italian scientist and father of modern anatomical pathology, Giovanni Battista Morgagni, published "De Sedibus Et Causis Morborum Per Anatomen Indagatis Libri Quinque". Despite centuries of study, pancreatic cancer remains one of the most formidable health challenges. It is the 14th most prevalent cancer globally, yet the 7th leading cause of cancer death, with the lowest survival rate. 📊 By the Numbers: In 2011, the five-year survival rate was just 3%. By 2021, this increased to 8%, demonstrating the impact of awareness and early detection campaigns. During the COVID-19 pandemic, the survival rate slightly declined to 7.3% in 2022. The global goal is to achieve a 13% five-year survival rate by 2030. This year's Pancreatic Cancer Awareness Month campaign theme, "A day of action, a world of difference," emphasizes the need for increased research, funding, and resources to support those impacted by the disease.

Latin America Conference on Lung Cancer will start tomorrow. Discover advancements in #lungcancer therapies, encompassing ongoing clinical trials and comprehensive insights into preclinical and early clinical breakthroughs.  Gain invaluable perspectives on addressing critical disparities in the region, arming yourself with actionable insights to drive change and enhance patient outcomes. If you would like to find information on similar events in one place, visit our Calendar of medical conferences, where you can filter events by date, location and cancer indications: https://lnkd.in/dnnmN4hD #oncology #medicalconference

Stay up to date with the latest developments in oncology - visit our Calendar of medical conferences. Don't miss out on upcoming events and conference news: https://lnkd.in/dnnmN4hD #Oncology #OncologyCompass

In 2022, 2.3 million women were diagnosed, and 670,000 died from the breast cancer disease. As women age, the risk increases. There is an increasing trend of women developing breast cancer even without a family history of it, which was previously one of the main screening factors for the disease. With nearly half of cases arising in women without known risk factors, the need for an updated approach to screening has never been clearer. Dr. Ritse M. Mann, PhD, a radiologist dedicated to optimizing care for breast cancer patients, is a leading force shaping the field. He advocates for a shift from a “one-size-fits-all” mammography model to more personalized, risk-based screening. This paradigm shift could enable earlier and more accurate detection, providing timely intervention and reducing the high costs of late-stage treatments. Investing in more effective screening systems and comprehensive risk assessment tools will be essential to improving outcomes. Read more: https://lnkd.in/dt787Q7A #BreastCancer #BreastCancerAwareness #EarlyDetection #Oncology #OncologyCompass

Multiple myeloma is an aggressive cancer characterized by terminally differentiated plasma cells. There is a significant unmet need for the identification of tolerable, targeted therapeutics for the elderly population representative of the disease. The overreliance on anti-apoptotic proteins is characteristic of MM, making these proteins attractive therapeutic targets. Venetoclax, previously approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), has previously been shown to be effective in a small subset of patients with MM. Recent research has demonstrated that the combination treatment of venetoclax and the demethylating agent, 5-azacytidine (5-aza), greatly increases sensitivity to venetoclax in multiple MM cell lines, meaning it is effective in a much broader patient population. Read more: https://lnkd.in/d3GA_KPE #oncology #Multiplemyeloma

The initial idea behind Digest, when we first launched Oncology Compass four years ago, was to create a quarterly publication 𝒃𝒚 𝒐𝒏𝒄𝒐𝒍𝒐𝒈𝒊𝒔𝒕𝒔, 𝒇𝒐𝒓 𝒐𝒏𝒄𝒐𝒍𝒐𝒈𝒊𝒔𝒕𝒔. This month, we proudly published the 11th issue of Oncology Compass Digest. Over the years, the Digest has remained true to its mission, providing the latest insights and updates in the constantly evolving field of oncology. We are proud to continue contributing to the community and supporting the exchange of knowledge. Take a look at the latest issue: https://lnkd.in/eKzrTZbG #OncologyCompass #Digest #Melanoma #BreastCancer #MelanomaAwareness #BreastCancerAwareness

If real life had a CTA button, what would it look like? During October, it would definitely look like a self-exam for breast cancer. Every October, we focus on raising awareness for the ongoing battle against breast cancer. At Capptoo, we believe that awareness is not just a word—it's a motivation to act. Think about how many CTA buttons you'll click today. Now, picture that number throughout October, over a year, or even a lifetime. Take a moment and consider how one real-life action, like a simple self-exam, could save your life. Our commitment to breast cancer awareness is unwavering, and we've been proud to contribute to several impactful projects—one of the many rewarding aspects of working in the life sciences industry. But our efforts continue beyond that. Whether we're developing innovative platforms like Oncology Compass, supporting awareness campaigns, or engaging in creative initiatives, we know that every small action counts. Ultimately, it's your action that truly matters—the one that can make a difference, the one that can save a life. As our Tanja Palm wisely says, "Take a moment this October to look after yourself. It could be the most important thing you do all year." Your health is your most valuable asset. #BreastCancerAwareness #PinkOctober #EarlyDetection #SelfCare #HealthAwareness #WearPink #CancerPrevention

📰 The latest edition of the Oncology Compass Digest is now live! 🔍 Inside This Issue: ℹ️ Early Detection Reimagined: An expert interview discussing the latest breast cancer screening and care changes. ℹ️ Fighting for Change: A feature on 19 years of colorectal cancer advocacy, highlighting the tireless efforts to improve access to screening and treatment. ℹ️ FDA Breakthrough: Discover the latest update from the FDA, which has granted accelerated approval to lifileucel, the first TIL therapy for advanced melanoma. 📚 Feature Story: The MySkinCheck Campaign emphasizes the importance of skin health and melanoma prevention. Read about the initiative's impact on early detection through mole checks, both onsite and online. Explore Digest #11 now: https://lnkd.in/eKzrTZbG #OncologyCompass #CancerResearch #PatientCare #BreastCancer #ColorectalCancer

🎗️Pink October: A Time for Awareness and Compassion 🌸 During this Breast Cancer Awareness Month, let’s honour survivors, support those battling, and encourage everyone to prioritize early detection. Screening saves lives; let’s make it a priority 💪 #BreastCancerAwareness #PinkOctober